Eversept Partners LP Takes Position in Palisade Bio, Inc. $PALI

Eversept Partners LP acquired a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,391,548 shares of the company’s stock, valued at approximately $12,670,000. Eversept Partners LP owned approximately 3.62% of Palisade Bio at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. BIT Capital GmbH bought a new position in shares of Palisade Bio during the 4th quarter valued at about $717,000. B Group Inc. bought a new position in shares of Palisade Bio during the 4th quarter valued at about $10,575,000. Persistent Asset Partners Ltd bought a new position in shares of Palisade Bio during the 4th quarter valued at about $978,000. Platinum Investment Management Ltd. bought a new position in shares of Palisade Bio during the 4th quarter valued at about $1,561,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Palisade Bio during the 4th quarter valued at about $110,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Stock Performance

PALI stock opened at $1.76 on Thursday. The stock has a market cap of $305.50 million, a P/E ratio of -1.74 and a beta of 1.52. The firm has a 50 day simple moving average of $1.97 and a 200 day simple moving average of $1.90. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Sell-side analysts predict that Palisade Bio, Inc. will post -0.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PALI. HC Wainwright began coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective for the company. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Stifel Nicolaus began coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.